Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900

DIAN-TU Phase 3 Clinical Trials, Topline Results

DIAN-TU Phase 3 Clinical Trials, Topline Results
Share or Print this page
Share or Print this page
February 10, 2020

Share or Print this page
CHICAGO, February 10, 2020 —This morning, Washington University School of Medicine in St. Louis announced topline Phase III clinical trial results of gantenerumab (Roche) and solanezumab (Lilly) for the prevention of cognitive and clinical decline in individuals with dominantly inherited Alzheimer’s disease. Neither gantenerumab or solanezumab met its primary outcome, which was a slowing of cognitive decline as measured by multiple tests of thinking and memory.
“While the top-line data fell short, the Alzheimer’s Association looks forward to a more complete report at upcoming scientific conferences,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer. “We learn from every clinical trial. In these findings there will be valuable lessons on how to best conduct clinical trials in people with and at risk for Alzheimer’s, and where to focus our energies moving forward. The Alzheimer’s Association will continue to partner in innovative studies like DIAN-TU. We thank the DIAN-TU participants and their families, and praise the researchers for the thoughtful and flexible design of the study, and their dogged pursuit of answers about treating and preventing Alzheimer’s.”

The Alzheimer’s Association provided $4.2 million in funding to the Dominantly Inherited Alzheimer’s Network (DIAN) to build the essential infrastructure for its Trials Unit. The Association then provided additional funding to the clinical trials, bringing the total to $11 million.
Dominantly inherited Alzheimer’s disease is a rare but devastating inherited, early-onset form of Alzheimer’s that is caused by mutations on chromosomes 21, 14 and 1. The mutations play a role in the breakdown of amyloid proteins and the formation of amyloid plaques. If a mother or father carries the mutation, their child has a 50/50 chance of inheriting it. People who inherit the mutation are all but guaranteed to develop symptoms of younger onset Alzheimer’s — at about the same age their parents did — starting in their 50s, 40s or 30s.

Alzheimer's Association

The Alzheimer’s Association is the leading voluntary health organization in Alzheimer's care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. Visit or call 800.272.3900.

Keep Up With Alzheimer’s News and Events